Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 10/20 | 0.38 |
| ▸ | KDR | P35968 | 10/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108759 | 0.86 | HSPB1 (0.45) | HSPB1S1PR4MAPTALDH1A1MAPK1 | |
| SCHEMBL14230559 | 0.86 | HSPB1 (0.45) | HSPB1S1PR4MAPTALDH1A1MAPK1 | |
| SCHEMBL306344 | 0.86 | HSPB1 (0.45) | HSPB1S1PR4MAPTALDH1A1MAPK1 | |
| SCHEMBL3568082 | 0.86 | MET (0.51) | HSPB1S1PR4MAPTALDH1A1MAPK1 | |
| SCHEMBL13168660 | 0.85 | KDR (0.44) | HSPB1MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3565390 | 0.85 | HSPB1 (0.42) | HSPB1S1PR4MAPTALDH1A1MAPK1 | |
| SCHEMBL3568638 | 0.85 | HSPB1 (0.42) | HSPB1S1PR4MAPTALDH1A1MAPK1 | |
| SCHEMBL307636 | 0.84 | HSPB1 (0.44) | HSPB1S1PR4MAPTALDH1A1MAPK1 | |
| SCHEMBL27811860 | 0.84 | KDR (0.47) | HSPB1MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3568582 | 0.84 | MET (0.53) | HSPB1S1PR4MAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20130310564-A1 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors | METHYLGENE INC. (CA) | 2013-11-21 | — | — | US | disclosed |
| US-8569503-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| WO-2007054831-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | HSPB1 3979/4885S1PR4 3707/4885MAPT 1952/4885 |
| US-20130310564-A1 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors | MAP3K19, MAP3K15, MAP3K9 | HSPB1 3924/4885S1PR4 3866/4885MAPT 1835/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | HSPB1 3979/4885S1PR4 3707/4885MAPT 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.